法国前列腺特异性抗原检测与前列腺癌管理的全国综合调查:揭示区域与时间差异
该研究基于法国国家健康登记库,分析2006至2018年间4936750名男性的前列腺特异性抗原(PSA)检测与前列腺癌管理数据,其中诊断前列腺癌者692516例,对照3899509例。研究发现首次PSA检测年龄偏晚(高峰在65至75岁),监测采用率低(12%),且2011年起诊断时转移性疾病(以全身治疗使用为指标)逐渐增加;老年男性诊断晚、治愈机会减少且死亡率增加,但需谨慎解读竞争性死因影响。
要点
- 50%的男性接受过五次PSA血液检测,但首次检测年龄偏晚,高峰在65至75岁。
- 监测采用率低(12%),且2011年起以全身治疗为指标的诊断时转移 incidence 逐渐增加。
- 老年男性诊断晚、治愈机会减少且死亡率增加,但需谨慎解读竞争性死因影响。
核心结论
- 法国首次PSA检测年龄偏晚,导致诊断晚、治愈机会减少且死亡率增加,但需谨慎解读竞争性死因影响。
- 监测采用率低(12%),2011年起诊断时转移性疾病(以全身治疗使用为指标)逐渐增加。
研究设计与样本
- 基于法国国家健康登记库的全国真实实践分析,纳入4936750名男性,其中前列腺癌患者692516例,对照3899509例。
- 记录2006至2018年间所有PSA血液检测,分析PSA检测、诊断年龄、治疗及生存,并按年龄组和法国不同地区比较管理方式。
主要发现
- 50%的男性接受过五次PSA血液检测,但首次PSA检测年龄偏晚,高峰在65至75岁。
- 监测采用率低(12%)。
- 老年男性诊断晚、治愈机会减少且死亡率增加,但需谨慎解读竞争性死因影响。
- 诊断时转移 incidence(以全身治疗使用为指标)从2011年起逐渐增加。
关键数值与推荐
- 监测采用率为12%。
- 50%的男性接受过五次PSA血液检测。
- 首次PSA检测年龄高峰在65至75岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需谨慎解读数据,因存在竞争性发病和其他死因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report nationwide real-life practice in the management of prostate cancer (PC) in France in a population of 4936750 men. All prostate-specific antigen (PSA) blood tests performed between 2006 and 2018 were recorded in a National Health registry, which allowed to identify 692516 men diagnosed with PC and a control population consisting of 3899509 men without PC. PSA tests, age at diagnosis, treatments, and survival were analysed. Their management was analysed by age range and compared in the different French regions. Disparities were found in age at PSA testing and management approaches (surveillance, and local and systemic therapies). We found that 50% of men had received five PSA blood tests, but the first PSA test was taken late in life, with a peak in the decade between 65 and 75 yr of age. Adoption of monitoring was low (12%). Older men appeared to receive a late diagnosis with reduced chances of curative therapy and a subsequent increase in mortality, but cautious interpretation of our data is warranted in view of competing morbidities and other causes of death. The incidence of metastases at diagnosis, indicated by the use of systemic therapies, increased progressively from 2011 onwards. PATIENT SUMMARY: In this study, we report nationwide real-life practice in the management of prostate cancer (PC) in France in a population of 4936750 men, including 692516 patients with PC. We found that the first prostate-specific antigen test is taken too late in life, leading to a late diagnosis with reduced chances of curative therapy and a subsequent increase in mortality.
引用
- Cussenot O, Taille Y, Portal JJ, et al. A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities. Eur Urol Oncol. 2024. PMID: 38472031. doi:10.1016/j.euo.2024.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。